Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system

[1]  G. Moreno-Bueno,et al.  Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance , 2007, Breast Cancer Research and Treatment.

[2]  C. Waters,et al.  Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. , 2006, Cancer research.

[3]  D. Yee,et al.  Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens , 2006, Breast Cancer Research and Treatment.

[4]  E. Giovannetti,et al.  Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma , 2005, British Journal of Cancer.

[5]  Shadan Ali,et al.  Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells , 2005, Breast Cancer Research and Treatment.

[6]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[7]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[8]  K. Vermeulen,et al.  Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. , 2003, International journal of radiation oncology, biology, physics.

[9]  R. Fimmers,et al.  Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines. , 2003, Anticancer research.

[10]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  N. Chandler,et al.  Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine , 2003, Journal of Gastrointestinal Surgery.

[12]  M. Highley,et al.  The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors , 2002, Anti-cancer drugs.

[13]  P. Sánchez‐Rovira,et al.  Evaluation of a Gemcitabine‐Doxorubicin‐Paclitaxel Combination Schedule through Flow Cytometry Assessment of Apoptosis Extent Induced in Human Breast Cancer Cell Lines , 2002, Japanese journal of cancer research : Gann.

[14]  W. Lam,et al.  Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. , 2002, Cancer research.

[15]  G. Shapiro,et al.  Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. , 2002, Cancer research.

[16]  Wing Lam,et al.  Phosphorylation of Pyrimidine Deoxynucleoside Analog Diphosphates , 2002, The Journal of Biological Chemistry.

[17]  P Ubezio,et al.  Cell cycle effects of gemcitabine , 2001, International journal of cancer.

[18]  W. Plunkett,et al.  S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. , 2001, Cancer research.

[19]  M. Tsao,et al.  Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. , 2000, Cancer research.

[20]  G. Rosner,et al.  Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Yee,et al.  Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects , 1999, Breast Cancer Research and Treatment.

[22]  G. Peters,et al.  Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Peters,et al.  Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. , 1999, European journal of cancer.

[24]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[25]  W. Plunkett,et al.  Preclinical characteristics of gemcitabine , 1995, Anti-cancer drugs.

[26]  D. Ross,et al.  Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. , 1994, Biochemical pharmacology.

[27]  J. Laliberté,et al.  Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. , 1993, Biochemical pharmacology.

[28]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[29]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Y Z Xu,et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.

[31]  A. Isetta,et al.  MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. , 1990, Journal of immunological methods.

[32]  M. Luscombe,et al.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. , 1987, British Journal of Cancer.

[33]  A. Hill.  The Combinations of Haemoglobin with Oxygen and with Carbon Monoxide. I. , 1913, The Biochemical journal.

[34]  Peng Huang,et al.  Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event , 2004, Cancer Chemotherapy and Pharmacology.

[35]  J. Hainsworth,et al.  Randomized P hase I I C omparison o f D ose-Intense Gemcitabine: T hirty-Minute I nfusion a nd F ixed D ose R ate Infusion i n P atients W ith P ancreatic A denocarcinoma , 2003 .

[36]  T. Lawrence,et al.  The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization , 2000, Cancer Chemotherapy and Pharmacology.